PROTEK Group is one of the largest pharmaceutical companies in Russia.
PROTEK Group was established in 1990. In 30 years the small company has become the largest Russian pharmaceutical holding, has overcome various development stages, including formation of CV PROTEK distribution business, development of retail pharmacy chain Rigla and expansion of Sotex production.
Crucial development stage of the company manifested itself in entry to public capital market by means of IPO in 2010.
Currently, PROTEK Group has a diversified business structure, and is present in all main segments of pharmaceutical industry:
- • production of medicinal products (Sotex, PharmFirm JSC Rafarma);
- • distribution of pharmaceutical products and beauty and wellness products (CV PROTEK);
- • retail trade (pharmacy chain Rigla).
The total number of the group’s employees exceeds than 17 thousand people. According to half-year 2019 results, consolidated revenue of CV PROTEK amounted to 125,161 mln RUB (audit data).
The practice of the Group business is focused both on increasing the competitiveness and sustainability of the Group unified business. In its development, PROTEK focuses on technological effectiveness and innovations.
For PROTEK Group, principle of transparency and publicity is the top priority. The Group pursues reasonable credit and financial policy and adheres to International Financial Reporting Standards (IFRS). Since 2010, PROTEK is a public company; PROTEK shares are traded at MICEX Stock Exchange.
Protek’s CFO Mikhail Danilov Featured in Choiseul 100 Russia Rating
CV Protek’s CFO Mikhail Danilov was features in Choiseul 100 Russia rating of young economic leaders by the French ind... more...
Protek Group headed the list of pharmaceutical companies in Expert-400 rating
Protek Group ranked 59th among largest Russian companies by 2019 revenue in the Expert-400 rating. more...
Protek Group ranked 57 among Russia’s 100 Largest Companies
Protek Group was ranked 57th among largest Russian companies rated by 219 revenue in the RBC-500 Rating. more...